September 4, 2024
(Reuters) – The U.S. Drug Enforcement Administration (DEA) has increased the production limit for Takeda Pharmaceutical’s ADHD drug Vyvanse and its generic versions by about 24% […]
September 4, 2024
In a fiercely competitive healthcare landscape, hospitals are pulling out all the stops to lure top nursing talent through their doors. From offering eye-popping sign-on bonuses […]
September 4, 2024
TOPLINE: Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) treated with immune checkpoint inhibitors (ICIs) show comparable survival outcomes whether they continued […]
September 4, 2024
TOPLINE: Nearly 80% of patients with metastatic uveal melanoma experienced skin toxicities with tebentafusp, a targeted immunotherapy, according to a study that also suggests that the […]
September 4, 2024
TOPLINE: Prehospital pulse-dose glucocorticoid treatment in patients with ST-segment elevation myocardial infarction (STEMI) does not reduce the final infarct size at 3 months but may improve […]
September 4, 2024
TOPLINE: Nearly 45% of cancer survivors face financial hardship during and after their cancer care, with factors including higher social vulnerability, younger age, lower income, and […]
September 4, 2024
TOPLINE: An impaired central sensitivity to thyroid hormone may be associated with an increased risk for death in patients with chronic kidney disease (CKD) and normal […]
September 4, 2024
TOPLINE: Higher rheumatoid arthritis (RA) disease activity is associated with an accelerated kidney function decline and increased risk for chronic kidney disease (CKD) stages G3a and […]
September 4, 2024
LONDON (Reuters) – Intermittent shortages of diabetes drug Ozempic in the European Union that are expected to continue into the final quarter of 2024 because of […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487
Next page